PRISM BioLab Co Ltd, a discovery and development biotechnology company, announced on Thursday that a combination study of E7386 and Lenvatinib mesylate codeveloped with its partner Eisai Co Ltd (TYO:4523) will be presented by Eisai at the American Society of Clinical Oncology (ASCO) Congress 2025, in Chicago, USA from 30 May to 3 June 2025.

An open-label Phase Ib study, treating advanced endometrial cancer patients progressed following platinum-based chemotherapy and anti-PD-(L)1 immunotherapy, enrolled 30 patients. With nine patients remaining on treatment, 30% (nine patients) showed the confirmed response (decrease of tumour size >30%) for an overall response rate of 30.0%. Among patients without prior Lenvatinib treatment, the overall response rate was 42.9%.

An abstract of the study has been released.

The results confirmed promising preliminary anti-tumour activity of E7386 + Lenvatinib with a manageable safety profile.